VYGR Key Statistics, Chart & Performance
The current stock price of VYGR is 4.09 USD. In the past month the price decreased by -5.32%. In the past year, price decreased by -24.95%.
VYGR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.7 | 412.54B | ||
| AMGN | AMGEN INC | 15.62 | 183.97B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.89 | 122.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 18.05 | 85.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 828.43 | 55.82B | ||
| INSM | INSMED INC | N/A | 37.54B | ||
| NTRA | NATERA INC | N/A | 35.11B | ||
| BIIB | BIOGEN INC | 11.17 | 27.42B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.09 | 21.69B | ||
| INCY | INCYTE CORP | 17.22 | 21.71B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About VYGR
Company Profile
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. The company is headquartered in Lexington, Massachusetts and currently employs 172 full-time employees. The company went IPO on 2015-11-11. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.
Company Info
VOYAGER THERAPEUTICS INC
75 Hayden Avenue
Lexington MASSACHUSETTS 02139 US
CEO: G. Andre Turenne
Employees: 172
Phone: 18572595340
VOYAGER THERAPEUTICS INC / VYGR FAQ
What does VYGR do?
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. The company is headquartered in Lexington, Massachusetts and currently employs 172 full-time employees. The company went IPO on 2015-11-11. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.
What is the stock price of VOYAGER THERAPEUTICS INC today?
The current stock price of VYGR is 4.09 USD. The price increased by 1.74% in the last trading session.
Does VYGR stock pay dividends?
VYGR does not pay a dividend.
How is the ChartMill rating for VOYAGER THERAPEUTICS INC?
VYGR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in VOYAGER THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VYGR.
Is VOYAGER THERAPEUTICS INC (VYGR) expected to grow?
The Revenue of VOYAGER THERAPEUTICS INC (VYGR) is expected to decline by -60.65% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
VYGR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to VYGR. When comparing the yearly performance of all stocks, VYGR is a bad performer in the overall market: 86.3% of all stocks are doing better.
VYGR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VYGR. No worries on liquidiy or solvency for VYGR as it has an excellent financial health rating, but there are worries on the profitability.
VYGR Financial Highlights
Over the last trailing twelve months VYGR reported a non-GAAP Earnings per Share(EPS) of -2.16. The EPS decreased by -404.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.75% | ||
| ROE | -57.27% | ||
| Debt/Equity | 0 |
VYGR Forecast & Estimates
18 analysts have analysed VYGR and the average price target is 15.3 USD. This implies a price increase of 274.08% is expected in the next year compared to the current price of 4.09.
For the next year, analysts expect an EPS growth of -88.71% and a revenue growth -60.65% for VYGR